NCT04554277View on ClinicalTrials.gov

Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure

NARecruitingINTERVENTIONAL
Enrollment

710

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

April 27, 2026

Study Completion Date

January 31, 2027

Conditions
Heart Failure
Interventions
BIOLOGICAL

Biomarker guided therapy

Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.

Trial Locations (12)

34295

ACTIVE_NOT_RECRUITING

Lapeyronie Hospital, Montpellier

Unknown

RECRUITING

CHU Angers, Angers

RECRUITING

CHU Besançon, Besançon

RECRUITING

CH Béziers, Béziers

RECRUITING

CHU Caen, Caen

RECRUITING

CHU Grenoble, Grenoble

RECRUITING

Arnaud de Villeneuve Hospital, Montpellier

RECRUITING

CHU Nimes, Nîmes

NOT_YET_RECRUITING

APHP Pompidou, Paris

NOT_YET_RECRUITING

CHU Rennes, Rennes

RECRUITING

CHU Toulouse, Toulouse

RECRUITING

CHU Vannes, Vannes

Sponsors

Collaborators (1)

EURO BIO Scientific
All Listed Sponsors
collaborator

EURO BIO Scientific

UNKNOWN

lead

University Hospital, Montpellier

OTHER

NCT04554277 - Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure | Biotech Hunter | Biotech Hunter